Activation profile of T cells from tumor site or peripheral blood of patients with B-NHL
. | . | Gated on CD3+CD4+ T cells‡ . | . | . | . | . | . | . | Gated on CD3+CD8+ T cells‡ . | . | . | . | . | . | . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tissue* . | Tumor† . | CD25 (IL-2R-α) . | CD122 (IL-2R-β) . | CD44 . | CD62L . | CD69 . | HLA-DR . | CD95 . | CD25 (IL-2R-α) . | CD122 (IL-2R-β) . | CD44 . | CD62L . | CD69 . | HLA-DR . | CD95 . | ||||||||||||
| LN | FL | 24 | 54 | 88 | 8 | 78 | 66 | 99 | 10 | 64 | 74 | 10 | 61 | 69 | 94 | ||||||||||||
| LN | CLL | 4 | ND | 92 | 2 | 28 | 24 | 94 | 0 | ND | 89 | 8 | 28 | 44 | 99 | ||||||||||||
| LN | FL | 7 | 15 | 31 | 1 | 27 | 42 | 97 | 1 | 14 | 9 | 1 | 30 | 69 | 99 | ||||||||||||
| LN | CLL | 10 | 16 | 89 | 5 | 45 | 34 | 79 | 3 | 16 | 95 | 4 | 22 | 22 | 47 | ||||||||||||
| LN | FL | 17 | 4 | 3 | 3 | 50 | 76 | 95 | 15 | 6 | 2 | 4 | 46 | 65 | 92 | ||||||||||||
| LN | FL | 15 | 2 | 60 | 16 | 67 | 77 | 98 | 14 | 2 | 65 | 14 | 60 | 72 | 95 | ||||||||||||
| PBL | CLL | 1 | 19 | 91 | 11 | 0 | 10 | 4 | 0 | 24 | 87 | 3 | 2 | 16 | 2 | ||||||||||||
| PBL | CLL | 10 | 5 | 99 | 6 | 0 | 10 | 41 | 0 | 4 | 99 | 4 | 1 | 15 | 17 | ||||||||||||
| PBL | CLL | 2 | 1 | 99 | 23 | 0 | 5 | 27 | 0 | 1 | 99 | 8 | 0 | 9 | 10 | ||||||||||||
| PBL | CLL | 2 | 3 | 99 | 5 | 0 | 27 | 24 | 1 | 4 | 98 | 1 | 1 | 50 | 14 | ||||||||||||
| PBL | CLL | 1 | 3 | 77 | 1 | 1 | 3 | 23 | 1 | 3 | 82 | 1 | 2 | 10 | 13 | ||||||||||||
. | . | Gated on CD3+CD4+ T cells‡ . | . | . | . | . | . | . | Gated on CD3+CD8+ T cells‡ . | . | . | . | . | . | . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tissue* . | Tumor† . | CD25 (IL-2R-α) . | CD122 (IL-2R-β) . | CD44 . | CD62L . | CD69 . | HLA-DR . | CD95 . | CD25 (IL-2R-α) . | CD122 (IL-2R-β) . | CD44 . | CD62L . | CD69 . | HLA-DR . | CD95 . | ||||||||||||
| LN | FL | 24 | 54 | 88 | 8 | 78 | 66 | 99 | 10 | 64 | 74 | 10 | 61 | 69 | 94 | ||||||||||||
| LN | CLL | 4 | ND | 92 | 2 | 28 | 24 | 94 | 0 | ND | 89 | 8 | 28 | 44 | 99 | ||||||||||||
| LN | FL | 7 | 15 | 31 | 1 | 27 | 42 | 97 | 1 | 14 | 9 | 1 | 30 | 69 | 99 | ||||||||||||
| LN | CLL | 10 | 16 | 89 | 5 | 45 | 34 | 79 | 3 | 16 | 95 | 4 | 22 | 22 | 47 | ||||||||||||
| LN | FL | 17 | 4 | 3 | 3 | 50 | 76 | 95 | 15 | 6 | 2 | 4 | 46 | 65 | 92 | ||||||||||||
| LN | FL | 15 | 2 | 60 | 16 | 67 | 77 | 98 | 14 | 2 | 65 | 14 | 60 | 72 | 95 | ||||||||||||
| PBL | CLL | 1 | 19 | 91 | 11 | 0 | 10 | 4 | 0 | 24 | 87 | 3 | 2 | 16 | 2 | ||||||||||||
| PBL | CLL | 10 | 5 | 99 | 6 | 0 | 10 | 41 | 0 | 4 | 99 | 4 | 1 | 15 | 17 | ||||||||||||
| PBL | CLL | 2 | 1 | 99 | 23 | 0 | 5 | 27 | 0 | 1 | 99 | 8 | 0 | 9 | 10 | ||||||||||||
| PBL | CLL | 2 | 3 | 99 | 5 | 0 | 27 | 24 | 1 | 4 | 98 | 1 | 1 | 50 | 14 | ||||||||||||
| PBL | CLL | 1 | 3 | 77 | 1 | 1 | 3 | 23 | 1 | 3 | 82 | 1 | 2 | 10 | 13 | ||||||||||||
ND indicates not done.
Lymphocytes were isolated from peripheral blood (PBL) or involved lymph nodes (LNs).
Patients had follicular lymphoma (FL) or chronic lymphocytic leukemia (CLL).
Results of flow cytometry analysis were expressed as the percentage of positive cells for each of the indicated markers in either the CD3+CD4+ or CD3+CD8+ subsets.